Synjardy

Synjardy is a combination oral medication used to treat type 2 diabetes mellitus.

Contents:

  • Empagliflozin (SGLT2 inhibitor)
  • Metformin (biguanide)

Mechanism of Action:

  • Empagliflozin: Inhibits sodium-glucose co-transporter 2 (SGLT2) in the renal proximal tubule → increases urinary glucose excretion → lowers blood glucose.
  • Metformin: Decreases hepatic glucose production and improves insulin sensitivity.

Indications:

  • Type 2 diabetes (to improve glycemic control)
  • Also beneficial in patients with cardiovascular risk or heart failure (due to empagliflozin)

Common Side Effects:

  • Empagliflozin: Genital infections, dehydration, hypotension, ketoacidosis (rare)
  • Metformin: GI upset, lactic acidosis (rare but serious)

Contraindications:

  • Severe renal impairment (due to metformin’s lactic acidosis risk)
  • Acute or chronic metabolic acidosis

Clinical Tip for Students:

Synjardy is useful when dual therapy is needed and can reduce pill burden. Always assess renal function before initiating or continuing therapy.

Let me know if you’d like it in a comparison table with similar agents.

Links